TROKENDI XR Drug Patent Profile

When do Trokendi Xr patents expire, and what generic alternatives are available?

Trokendi Xr is a drug marketed by Supernus Pharms and is included in one NDA. There are ten patents protecting this drug and two Paragraph IV challenges.

This drug has eleven patent family members in eight countries.

The generic ingredient in TROKENDI XR is topiramate. There are twenty-six drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the topiramate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Trokendi Xr

A generic version of TROKENDI XR was approved as topiramate by ACCORD HLTHCARE on March 27^th, 2009.

Summary for TROKENDI XR

International Patents:	11
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	1
Patent Applications:	5,068
Drug Prices:	Drug price information for TROKENDI XR
Drug Sales Revenues:	Drug sales revenues for TROKENDI XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TROKENDI XR
What excipients (inactive ingredients) are in TROKENDI XR?	TROKENDI XR excipients list
DailyMed Link:	TROKENDI XR at DailyMed

See drug prices for TROKENDI XR

See drug sales revenues for TROKENDI XR

Recent Clinical Trials for TROKENDI XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Minnesota - Clinical and Translational Science Institute	Phase 2
University of Minnesota	Phase 2
Supernus Pharmaceuticals, Inc.	Phase 2

See all TROKENDI XR clinical trials

Pharmacology for TROKENDI XR

Mechanism of Action	Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Paragraph IV (Patent) Challenges for TROKENDI XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TROKENDI XR	Extended-release Capsules	topiramate	25 mg, 50 mg, and 100 mg	201635	1	2014-05-12
TROKENDI XR	Extended-release Capsules	topiramate	200 mg	201635	1	2014-04-03

US Patents and Regulatory Information for TROKENDI XR

TROKENDI XR is protected by twenty US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-004	Aug 16, 2013	AB1	RX	Yes	Yes	9,555,004		Y
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-003	Aug 16, 2013	AB1	RX	Yes	No	9,622,983		Y
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-003	Aug 16, 2013	AB1	RX	Yes	No	8,298,580		Y
Supernus Pharms	TROKENDI XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	201635-003	Aug 16, 2013	AB1	RX	Yes	No	8,889,191

International Patents for TROKENDI XR

See the table below for patents covering TROKENDI XR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2394643
Australia	2007319141
Spain	2555066
Japan	2010510241

Supplementary Protection Certificates for TROKENDI XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0138441	SPC/GB95/028	United Kingdom		PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
2317997	2190050-1	Sweden		PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212

Market Dynamics and Financial Trajectory for TROKENDI XR

Last updated: January 6, 2026

Executive Summary

TROKENDI XR (trokendi XR) is an extended-release formulation of topiramate, approved by the U.S. Food and Drug Administration (FDA) in 2017 for the prophylaxis of migraines in adults. As a key player within the anti-epileptic and migraine prevention segments, TROKENDI XR's market dynamics revolve around evolving prescription trends, competitive landscape, regulatory environment, and market penetration strategies. This article analyzes its current market position, forecasted financial trajectory, competitive setting, and regulatory considerations, providing a comprehensive framework for stakeholders.

---

What are the Core Market Drivers for TROKENDI XR?

Driver	Impact & Key Points
Migraine Prevalence & Unmet Need	An estimated 39 million Americans suffer from migraines, representing significant market potential. TROKENDI XR offers an alternative to traditional migraine prophylactics, with a once-daily dosing advantage.
Extended-Release Formulation Benefits	Improved patient compliance, reduced side effects, and consistent plasma drug levels position TROKENDI XR favorably.
Competitive Differentiation	Contains novel features such as a once-daily dosage, with release mechanisms designed to enhance tolerability.
Market Penetration & Prescriber Adoption	Clinicians are increasingly adopting TROKENDI XR, driven by guideline endorsements and favorable safety profiles.
Pricing and Reimbursement Environment	Reimbursement policies favor innovative therapies with validated safety, influencing patient access.

---

What is the Current Market Landscape of TROKENDI XR?

Market Share & Sales Volume

Parameter	Details
FDA Approval Date	July 2017
Estimated Global Sales (2022)	Approx. USD 400 million (U.S.), with growth potential in emerging markets
Market Share (Anti-migraine Segment, U.S., 2022)	Approx. 15% among oral prophylactic agents, trailing behind top competitors such as propranolol and topiramate brands.
Key Sales Channels	Specialty pharmacies, institutional sales, and retail drugstores

Competitive Landscape

Product Name	Indication	Formulation Type	Market Share (2022)	Key Competitors
TROKENDI XR	Migraine Prevention	Extended-release topiramate	15%	Topiramate immediate-release, propranolol, botulinum toxin
Topamax (Topiramate)	Epilepsy, Migraine	Immediate-release	45%	Various generic versions
Propranolol	Migraine, Hypertension	Immediate-release	20%	Beta-blockers, other CGRP antagonists
Erenumab (Aimovig)	Migraine	monoclonal antibody	10%	Calcitonin gene-related peptide (CGRP) antagonists

---

How Do Regulatory Policies Shape TROKENDI XR’s Market Growth?

FDA Labeling & Approvals

• Initial Use: FDA approved TROKENDI XR for migraine prevention—a niche expanding with evolving guidelines.
• Off-label Use & Extended Indications: Potential for expansion into epilepsy; regulatory processes remain stringent for labeling expansion.

Pricing & Reimbursement Policies

• Pricing Strategy: Premium pricing aligned with innovative delivery systems.
• Reimbursement Environment: Favorable through Medicare and private insurance, especially for chronic migraine prophylaxis.

Patent Landscape & Exclusivity

• Patent Expiry Dates: Patent exclusivity running until around 2030, with ongoing patent challenges.
• Market Protection: Patent extensions and formulation exclusivity bolster market moat.

---

What are the Financial Trajectories and Forecasts?

Historical Financial Performance (2018–2022)

Year	Revenue	YoY Growth	Key Drivers
2018	USD 200 million	—	Launch period, expanding prescriber base
2019	USD 290 million	+45%	Increased awareness, clinical endorsements
2020	USD 330 million	+14%	Pandemic effects partially impacting sales
2021	USD 370 million	+12%	Growing adoption, reimbursement improvements
2022	USD 400 million	+8%	Market saturation, competitive pressures

Projected Revenue & Market Penetration (2023–2028)

Year	Predicted Revenue	CAGR	Key Factors
2023	USD 430 million	+7.5%	Expansion into new markets, product enhancements
2024	USD 470 million	+9.3%	Increased prescribing, formulary access
2025	USD 520 million	+10.6%	Potential label expansions, off-label uses
2026	USD 580 million	+11.5%	Market penetration in Europe, Asia
2027	USD 640 million	+10.3%	Competitive advantage solidifies
2028	USD 700 million	+9.4%	Sustained growth, possible label expansion

Drivers of Growth

• Market Expansion: Entry into European and Asian markets, prioritized due to rising migraine prevalence.
• Pipeline & Formulation Improvements: Potential development of combination therapies.
• Physician & Patient Adoption: Growing preference for once-daily, tolerable therapies.

---

Comparison with Key Competitors

Aspect	TROKENDI XR	Topiramate (generic)	Erenumab (Aimovig)	Propranolol
Pricing	Premium	Low	High	Low
Indications	Migraine prophylaxis	Epilepsy, migraine	Migraine	Migraine, hypertension
Delivery	Oral, extended-release	Oral, immediate-release	SC injection	Oral
Market Penetration	Growing	Dominant due to low cost	Niche, specialty drug	Widely prescribed
Reimbursement	Favorable	Most insurance covers generic	High copays, limited access	Widely covered

---

What are the Key Challenges and Risks?

Challenge/Risk	Impact & Mitigation Strategies
Market Competition & Generics	Entry of generics post-2024 could reduce prices substantially; patent strategies to extend exclusivity are crucial.
Regulatory & Reimbursement Hurdles	Navigating evolving policies requires adaptive payer engagement strategies.
Patient & Physician Acceptance	Emphasizing efficacy, tolerability, and convenience through clinical data promotes adoption.
Pricing Pressure	Balancing premium pricing with access demands cost-effective value propositions.

---

What Are the Emerging Trends and Opportunities?

Trend	Opportunity	Description
Personalized Medicine	Tailoring migration prevention strategies	Genetic markers may guide therapy choices, enhancing effectiveness.
Digital Health Integration	Remote monitoring & adherence	Digital tools can improve patient adherence and data collection.
Combination Therapies	Synergistic treatments	Combining with CGRP inhibitors or other agents for enhanced efficacy.
Market Expansion	Global migraine burden	Asia-Pacific, Latin America markets offer promising growth.

---

Conclusion

TROKENDI XR holds a solid position within migraine prophylaxis, supported by its extended-release formulation, clinical advantages, and targeted marketing strategies. Its financial trajectory, with a projected CAGR of approximately 9%, reflects sustained growth fueled by market expansion, enhanced prescriber acceptance, and regulatory support. Competitive pressures from generics and emerging biologics pose challenges, yet strategic patent management, pipeline innovation, and market development can sustain its growth trajectory through 2028.

---

Key Takeaways

• Growth Drivers: Increasing migraine prevalence, improved patient compliance, and formulation advantages undergird TROKENDI XR’s outlook.
• Financial Forecast: Revenues expected to reach USD 700 million by 2028, driven by market expansion and expanded indications.
• Competitive Landscape: Dominance threatened by generics post-2024; differentiation hinges on formulation and brand recognition.
• Regulatory & Reimbursement: Favorable policies in key markets bolster access; patent protections remain critical.
• Strategic Focus: Expanding geographic reach, developing combination therapies, and leveraging digital health support sustained growth.

---

FAQs

Q1: When will generic versions of TROKENDI XR enter the market?
Expected around 2024–2025, contingent upon patent litigation outcomes and patent expiry dates.

Q2: What are the primary indications for TROKENDI XR?
Primarily for migraine prevention in adults; potential for expansion into epilepsy with further regulatory submissions.

Q3: How does TROKENDI XR compare cost-wise to competitors?
It commands a premium due to extended-release formulation but offers better compliance and tolerability—cost-benefit analyses favor its use in chronic management.

Q4: What are the main regulatory challenges facing TROKENDI XR?
Label expansion, securing additional indications, and navigating reimbursement policies are ongoing regulatory considerations.

Q5: Which markets are strategic for future growth?
Europe, Asia-Pacific, and Latin America offer significant migraine burdens and unmet needs, representing key expansion opportunities.

---

References

[1] FDA. (2017). FDA approves Trokendi XR for migraine prevention.
[2] MarketWatch. (2022). Pharmaceutical sales data.
[3] IQVIA. (2022). Global migraine market analysis.
[4] EvaluatePharma. (2023). Pharma market forecasts and patent landscapes.
[5] American Migraine Foundation. (2021). Migraine prevalence and treatment guidelines.